Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Personalized approach to cytoprotective treatment in ischemic heart disease

Show simple item record

dc.contributor.author Chetruș, Olga
dc.date.accessioned 2023-05-07T10:59:11Z
dc.date.available 2023-05-07T10:59:11Z
dc.date.issued 2022
dc.identifier.citation CHETRUȘ, Olga. Personalized approach to cytoprotective treatment in ischemic heart disease. In: Revista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciences. 2022, vol. 30(4), pp. 16-21. ISSN 2345-1467. https://doi.org/10.52645/MJHS.2022.4.03 en_US
dc.identifier.issn 2345-1467
dc.identifier.uri https://cercetare.usmf.md/sites/default/files/inline-files/REVISTA%20DE%20%C8%98TIIN%C8%9AE%20ALE%20S%C4%82N%C4%82T%C4%82%C8%9AII%20DIN%20MOLDOVA%20NR.%204%2C%202022_0.pdf
dc.identifier.uri https://doi.org/10.52645/MJHS.2022.4.03
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/24216
dc.description.abstract Summary. Objectives. To assess the efficacy and harmlessness of the cytoprotective treatment with meldonium of ischemic heart disease by developing personalized approaches. Materials and methods. Our study included 160 patients with IHD (117 men and 43 women) aged 37 to 81 years. Of them, 142 patients had angina pectoris of stable effort from different functional classes, and 21 – unstable angina pectoris. The average age of patients was 59.26±0.74 years. All patients were divided into 2 groups: 1 group (n=80) only with background treatment and 2 group included (n=80) with background treatment and meldonium. The observation period was 12 months (one year). Results. Significant differences were found in the pathogenesis of the underlying pathology and in the effectiveness of meldonium treatment in men and women. In this way, for men on the background of exertion angina is characteristic of more frequent occurrence of myocardial infarction, and for women – heart failure and diabetes mellitus, but meldonium remain the same effectiveness for both groups. Men smoke 16 times more, and women suffer from abdominal obesity 2 times more, which could be the cause of the more atherogenic lipid profile in them. According to the survey, the hereditary predisposition to cardiovascular diseases is higher in women, although most likely women are simply better informed about the pathologies of relatives and they were more disciplined in treatment with meldonium. Discussions. The effectiveness of treatment in women is significantly better according to the indicators of subjective and objective improvement compared to men, which is confirmed by many existing studies. Sex factor determines the presence of a number of pathogenetic peculiarities of the course of ischemic heart disease, and therefore can be considered as one of the criteria for personalizing pharmacotherapy, however, for the individual choice of metabolic corrector, this factor is not significant. The age factor determines some pathogenetic peculiarities of the course of ischemic heart disease and the effectiveness of pharmacotherapy, however, it is not decisive for the choice of metabolic corrector. Conclusions. The standard criteria for the personalization of pharmacotherapy in cardiology - sex, age, environmental risk factors, the presence of an underlying disease and concomitant pathology, pharmacogenetic and psychological profile - affect the pathogenesis of the development of coronary artery disease, to some extent determining the sensitivity of patients to meldonium, but they are not decisive for a personalized choice of metabolic corrector. en_US
dc.language.iso en en_US
dc.publisher Instituţia Publică Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” din Republica Moldova en_US
dc.relation.ispartof Revista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciences en_US
dc.subject cardiocytoprotector en_US
dc.subject cardiac metabolism en_US
dc.subject ischemic heart disease en_US
dc.subject.ddc UDC: 616.127-005.4-085.272 en_US
dc.title Personalized approach to cytoprotective treatment in ischemic heart disease en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics